These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36087236)

  • 21. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
    Lee CC; Hsieh CC; Ko WC
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Why Molnupiravir Fails in Hospitalized Patients.
    Brown AN; Lang Y; Zhou J; Franco EJ; Hanrahan KC; Bulitta JB; Drusano GL
    mBio; 2022 Dec; 13(6):e0291622. PubMed ID: 36374076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
    Yip AJW; Low ZY; Chow VTK; Lal SK
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis.
    Amani B; Akbarzadeh A; Amani B; Shabestan R; Khorramnia S; Navidi Z; Rajabkhah K; Kardanmoghadam V
    J Med Virol; 2023 Jun; 95(6):e28889. PubMed ID: 37368841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials.
    Huang PY; Liu TH; Wu JY; Tsai YW; Lai CC
    J Med Virol; 2023 Mar; 95(3):e28621. PubMed ID: 36846901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
    Gentry CA; Nguyen P; Thind SK; Kurdgelashvili G; Williams RJ
    J Infect; 2023 Mar; 86(3):248-255. PubMed ID: 36702309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study.
    Gentile I; Scotto R; Schiano Moriello N; Pinchera B; Villari R; Trucillo E; Ametrano L; Fusco L; Castaldo G; Buonomo AR; Federico Ii Covid Team
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
    Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
    JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
    Imran M; Kumar Arora M; Asdaq SMB; Khan SA; Alaqel SI; Alshammari MK; Alshehri MM; Alshrari AS; Mateq Ali A; Al-Shammeri AM; Alhazmi BD; Harshan AA; Alam MT; Abida
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Tian F; Feng Q; Chen Z
    Int J Antimicrob Agents; 2023 Aug; 62(2):106870. PubMed ID: 37245600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis.
    Malin JJ; Weibel S; Gruell H; Kreuzberger N; Stegemann M; Skoetz N
    J Antimicrob Chemother; 2023 Jul; 78(7):1586-1598. PubMed ID: 37170886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study.
    Xie Y; Choi T; Al-Aly Z
    BMJ; 2023 Apr; 381():e074572. PubMed ID: 37161995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records.
    Xie Y; Bowe B; Al-Aly Z
    BMJ; 2023 Mar; 380():e072705. PubMed ID: 36882199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molnupiravir in COVID-19: A Scoping Review.
    Kaore S; Atal S
    Curr Drug Res Rev; 2022; 14(3):203-214. PubMed ID: 35638286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
    Sutanto ST; Sinto R; Pasaribu A; Shakinah S
    Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir.
    Quah KSE; Huang X; Renia L; Oon HH
    Ann Acad Med Singap; 2022 Dec; 51(12):774-786. PubMed ID: 36592146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real life experience of molnupiravir as a treatment of SARS-CoV-2 infection in vaccinated and unvaccinated patients: a letter on its effectiveness at preventing hospitalization.
    Scioscia G; De Pace CC; Giganti G; Tondo P; Foschino Barbaro MP; Lacedonia D
    Ir J Med Sci; 2023 Oct; 192(5):2301-2303. PubMed ID: 36454535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.